Table 1 Clinical and biochemical data of the study cohort.

From: MARC1 p.A165T variant is associated with decreased markers of liver injury and enhanced antioxidant capacity in autoimmune hepatitis

 

Entire cohort

Pure AIH

AIH-PSC

AIH-PBC

Total participants, n

313

206

107

Female, n (%)

218 (70%)

161 (78%)

57 (53%)

Age (years)

36 (18–84)

37 (18–84)

34 (18–68)

BMI (kg/m2)

23.0 (15.6–40.9)

23.6 (16.6–40.9)

22.6 (15.6–33.6)

Duration of the disease (years)

4.0 (0–37)

3.4 (0–37)

4.3 (0–27)

ALT (IUI/l, normal < 56)

54 (8–3400)

44 (8–3400)

94 (8–1233)

AST (IU/l, normal < 40)

44 (5–1543)

40 (16–1100)

72 (5–1543)

ALP (IU/l, normal < 120)

99 (23–1193)

85 (23–344)

184 (39–1193)

Bilirubin (mg/dl, normal < 1.2)

1.0 (0.2–34.1)

1.0 (0.2–34.1)

1.0 (0.2–18.6)

IgG (mg/dl, normal < 1600)

1488 (318–6508)

1475 (677–6508)

1508 (318–4381)

Platelets (G/l)

179 (21–667)

157 (21–519)

210 (21–667)

FIB-4 (points)

1.7 (0.1–37.7)

1.8 (0.2–37.7)

1.3 (0.1–14.3)

MELD (points)

8.5 (6.4–36.9)

8.5 (6.4–36.9)

7.7 (6.4–21.5)

LSM (kPa)

11.2 (4.0–74.0)

11.4 (4.0–52.4)

10.6 (4.4–74.0)

Treatment

Steroid-based therapy

217 (69%)

138 (64%)

79 (74%)

AZA monotherapy

21 (7%)

18 (8%)

3 (3%)

Other treatment or none

97 (31%)

59 (27%)

38 (36%)

  1. AIH autoimmune hepatitis, ALP alkaline phosphatase, ALT alanine aminotransferase, AST aspartate aminotransferase, AZA azathioprine, FIB-4 Fibrosis-4, IgG immunoglobulin G, kPa kilopascal, LSM liver stiffness measurement, MELD model of end-stage liver disease, PBC primary biliary cholangitis, PLT platelet count, PSC primary sclerosing cholangitis. Values are expressed as medians (ranges), unless stated otherwise.
Back to article page